{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:16:31Z","timestamp":1792988191336,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jpeds.2014.03.060","type":"journal-article","created":{"date-parts":[[2014,5,22]],"date-time":"2014-05-22T12:45:57Z","timestamp":1400762757000},"page":"600-605.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Thrombopoietic Agents for the Treatment of Persistent and Chronic Immune Thrombocytopenia in Children"],"prefix":"10.1016","volume":"165","author":[{"given":"Kavitha","family":"Ramaswamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Leven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela V.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Bussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2014.03.060_bib1","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa054626","article-title":"AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP","volume":"355","author":"Bussel","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2014.03.060_bib2","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2014.03.060_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind, randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2014.03.060_bib4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of Eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2014.03.060_bib5","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2014.03.060_bib6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2014.03.060_bib7","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jpeds.2014.03.060_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2014.03.060_bib9","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with Romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2014.03.060_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2010-10-313908","article-title":"A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2014.03.060_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/pbc.23312","article-title":"Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP)","volume":"58","author":"Klaassen","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jpeds.2014.03.060_bib12","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3109\/09537104.2011.619601","article-title":"Romiplostim therapy in children with unresponsive chronic immune thrombocytopenia","volume":"23","author":"Mokhtar","year":"2012","journal-title":"Platelets"},{"key":"10.1016\/j.jpeds.2014.03.060_bib13","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jpeds.2014.03.060_bib14","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with Romiplostim","volume":"114","author":"Kuter","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2014.03.060_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1185\/03007995.2011.644849","article-title":"Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia","volume":"28","author":"Fogarty","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jpeds.2014.03.060_bib16","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2014.03.060_bib17","first-page":"501","article-title":"Eltrombopag for the treatment of childhood chronic ITP: The PETIT study, a placebo-controlled clinical trial","volume":"97","author":"Bussel","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.jpeds.2014.03.060_bib18","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood.V122.21.3559.3559","article-title":"Safety and efficacy of eltrombopag at escalated doses up to 150 mg in patients with persistent and chronic immune thrombocytopenia (ITP) not responsive To 75 mg","volume":"311","author":"McGuinn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2014.03.060_bib19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3324\/haematol.2012.074633","article-title":"A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia","volume":"98","author":"Khellaf","year":"2013","journal-title":"Haemetalogica"},{"key":"10.1016\/j.jpeds.2014.03.060_bib20","first-page":"98","article-title":"Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romipolostim\u2014four European case studies","volume":"96","author":"Newland","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jpeds.2014.03.060_bib21","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood.V118.21.3281.3281","article-title":"Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the tpo receptor agonist romiplostim: report of 9 cases","volume":"118","author":"Bussel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2014.03.060_bib22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood.V120.21.1085.1085","article-title":"Successful discontinuation of eltrombopag treatment in patients with chronic ITP","volume":"120","author":"Leven","year":"2012","journal-title":"Blood"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347614003485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347614003485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T16:39:59Z","timestamp":1597855199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347614003485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0022347614003485"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2014.03.060","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombopoietic Agents for the Treatment of Persistent and Chronic Immune Thrombocytopenia in Children","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2014.03.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2014.05.030","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}